Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.

Nam SY, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB

International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity1 Aug 2001Cited by 57 (Europe PMC)

PMID11477493DOI10.1038/sj.ijo.0801636PepBankPUB-11477493

Source link PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In obese diabetic patients, the fraction of weight lost as fat was 0.98+/-0.39 with GH versus 0.52+/-0.32 kg/kg with placebo (P<0.05).
In plain wordsIn obese diabetic patients, a greater fraction of weight loss was fat with GH than placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseFraction of weight lost as fat
Study
n = 18
Comparator
Placebo with diet restriction
Outcome group
Body composition · Metabolic and weight
Studied dose
0.15 IU/kg body weight/week · 12 weeksAs given in this study (human).
Measurements
Fraction of body weight lost as fat
0.98 kg/kg
GH group, +/-0.39
Fraction of body weight lost as fat
0.52 kg/kg
placebo group, +/-0.32
Source sentences
Summary
The fraction of body weight lost as fat lost was significantly greater (0.98+/-0.39 vs 0.52+/-0.32 kg/kg, P<0.05) and visceral fat area was decreased more in the GH-treated group compared to the placebo-treated group (27.9 vs 21.6%, P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n=9; rhGH, 0.15 IU/kg body weight/week) or placebo (n=9) for 12 weeks.
Summary · context
Eighteen newly-diagnosed obese type 2 diabetic patients (age 42--56 y, body mass index 28.1+/-2.7 kg/m(2)).
Report a problemFND-1147749301
02HumanNon-randomized trialEfficacy outcome
In obese diabetic patients, visceral fat area decreased by 27.9% with GH versus 21.6% with placebo (P<0.05).
In plain wordsIn obese diabetic patients, GH reduced visceral fat area more than placebo.
Peptide
HGH (somatotropin)
Outcome
DecreaseVisceral fat area
Study
n = 18
Comparator
Placebo with diet restriction
Outcome group
Body composition · Metabolic and weight
Studied dose
0.15 IU/kg body weight/week · 12 weeksAs given in this study (human).
Measurements
Visceral fat area decrease
27.9%
GH group
Visceral fat area decrease
21.6%
placebo group
Source sentences
Summary
The fraction of body weight lost as fat lost was significantly greater (0.98+/-0.39 vs 0.52+/-0.32 kg/kg, P<0.05) and visceral fat area was decreased more in the GH-treated group compared to the placebo-treated group (27.9 vs 21.6%, P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n=9; rhGH, 0.15 IU/kg body weight/week) or placebo (n=9) for 12 weeks.
Summary · context
Eighteen newly-diagnosed obese type 2 diabetic patients (age 42--56 y, body mass index 28.1+/-2.7 kg/m(2)).
Report a problemFND-1147749302
03HumanNon-randomized trialEfficacy outcome
In obese diabetic patients, lean body mass increased with GH but decreased with placebo.
In plain wordsIn obese diabetic patients, lean body mass increased with GH but decreased with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseLean body mass
Study
n = 18
Comparator
Placebo with diet restriction
Outcome group
Body composition · Metabolic and weight
Studied dose
0.15 IU/kg body weight/week · 12 weeksAs given in this study (human).
Source sentences
Summary
Lean body mass and muscle area were reduced in the placebo-treated group, whereas an increase in both was observed in the GH-treated group.
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n=9; rhGH, 0.15 IU/kg body weight/week) or placebo (n=9) for 12 weeks.
Summary · context
Eighteen newly-diagnosed obese type 2 diabetic patients (age 42--56 y, body mass index 28.1+/-2.7 kg/m(2)).
Report a problemFND-1147749303
04HumanNon-randomized trialEfficacy outcome
In obese diabetic patients, muscle area increased with GH but decreased with placebo.
In plain wordsIn obese diabetic patients, muscle area increased with GH but decreased with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseMuscle area
Study
n = 18
Comparator
Placebo with diet restriction
Outcome group
Body composition · Metabolic and weight
Studied dose
0.15 IU/kg body weight/week · 12 weeksAs given in this study (human).
Source sentences
Summary
Lean body mass and muscle area were reduced in the placebo-treated group, whereas an increase in both was observed in the GH-treated group.
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n=9; rhGH, 0.15 IU/kg body weight/week) or placebo (n=9) for 12 weeks.
Summary · context
Eighteen newly-diagnosed obese type 2 diabetic patients (age 42--56 y, body mass index 28.1+/-2.7 kg/m(2)).
Report a problemFND-1147749304
05HumanNon-randomized trialEfficacy outcome
In obese diabetic patients, GDR increased from 4.67+/-1.05 to 6.95+/-0.91 mg/kg/min only in the GH group (P<0.05).
In plain wordsIn obese diabetic patients, glucose disposal increased from baseline only in the GH group.
Peptide
HGH (somatotropin)
Outcome
IncreaseGlucose disposal rate
Study
n = 9
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.15 IU/kg body weight/week · 12 weeksAs given in this study (human).
Measurements
Glucose disposal rate
4.67 mg/kg/min
GH group, first value, +/-1.05
Glucose disposal rate
6.95 mg/kg/min
GH group, second value, +/-0.91
Source sentences
Summary
GDR the was significantly increased in only the GH-treated group (4.67+/-1.05 vs 6.95+/-0.91 mg/kg/min, P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n=9; rhGH, 0.15 IU/kg body weight/week) or placebo (n=9) for 12 weeks.
Summary · context
Eighteen newly-diagnosed obese type 2 diabetic patients (age 42--56 y, body mass index 28.1+/-2.7 kg/m(2)).
Report a problemFND-1147749305
06HumanNon-randomized trialEfficacy outcome
In obese diabetic patients, serum glucose decreased significantly after GH treatment.
In plain wordsIn obese diabetic patients, serum glucose decreased after GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseSerum glucose
Study
n = 9
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.15 IU/kg body weight/week · 12 weeksAs given in this study (human).
Source sentences
Summary
Serum glucose levels and insulin- and FFA-area under the curve during OGTT and HbA(1c) were significantly decreased after GH treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n=9; rhGH, 0.15 IU/kg body weight/week) or placebo (n=9) for 12 weeks.
Summary · context
Eighteen newly-diagnosed obese type 2 diabetic patients (age 42--56 y, body mass index 28.1+/-2.7 kg/m(2)).
Report a problemFND-1147749307
07HumanNon-randomized trialEfficacy outcome
In obese diabetic patients, insulin AUC during OGTT decreased significantly after GH treatment.
In plain wordsIn obese diabetic patients, insulin after oral glucose decreased after GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseInsulin AUC during OGTT
Study
n = 9
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.15 IU/kg body weight/week · 12 weeksAs given in this study (human).
Source sentences
Summary
Serum glucose levels and insulin- and FFA-area under the curve during OGTT and HbA(1c) were significantly decreased after GH treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n=9; rhGH, 0.15 IU/kg body weight/week) or placebo (n=9) for 12 weeks.
Summary · context
Eighteen newly-diagnosed obese type 2 diabetic patients (age 42--56 y, body mass index 28.1+/-2.7 kg/m(2)).
Report a problemFND-1147749308
08HumanNon-randomized trialEfficacy outcome
In obese diabetic patients, FFA AUC during OGTT decreased significantly after GH treatment.
In plain wordsIn obese diabetic patients, free fatty acids after oral glucose decreased after GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseFFA AUC during OGTT
Study
n = 9
Outcome group
Lipids · Metabolic and weight
Studied dose
0.15 IU/kg body weight/week · 12 weeksAs given in this study (human).
Source sentences
Summary
Serum glucose levels and insulin- and FFA-area under the curve during OGTT and HbA(1c) were significantly decreased after GH treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n=9; rhGH, 0.15 IU/kg body weight/week) or placebo (n=9) for 12 weeks.
Summary · context
Eighteen newly-diagnosed obese type 2 diabetic patients (age 42--56 y, body mass index 28.1+/-2.7 kg/m(2)).
Report a problemFND-1147749309
09HumanNon-randomized trialEfficacy outcome
In obese diabetic patients, HbA(1c) decreased significantly after GH treatment.
In plain wordsIn obese diabetic patients, HbA1c decreased after GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseHbA1c
Study
n = 9
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.15 IU/kg body weight/week · 12 weeksAs given in this study (human).
Source sentences
Summary
Serum glucose levels and insulin- and FFA-area under the curve during OGTT and HbA(1c) were significantly decreased after GH treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n=9; rhGH, 0.15 IU/kg body weight/week) or placebo (n=9) for 12 weeks.
Summary · context
Eighteen newly-diagnosed obese type 2 diabetic patients (age 42--56 y, body mass index 28.1+/-2.7 kg/m(2)).
Report a problemFND-1147749310
10HumanNon-randomized trialEfficacy outcome
In obese diabetic patients, LDL cholesterol decreased only in the GH-treated group.
In plain wordsIn obese diabetic patients, LDL cholesterol decreased from baseline only in the GH group.
Peptide
HGH (somatotropin)
Outcome
DecreaseLDL cholesterol
Study
n = 9
Outcome group
Lipids · Metabolic and weight
Studied dose
0.15 IU/kg body weight/week · 12 weeksAs given in this study (human).
Source sentences
Summary
LDL-cholesterol level was decreased in only the GH-treated group.
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n=9; rhGH, 0.15 IU/kg body weight/week) or placebo (n=9) for 12 weeks.
Summary · context
Eighteen newly-diagnosed obese type 2 diabetic patients (age 42--56 y, body mass index 28.1+/-2.7 kg/m(2)).
Report a problemFND-1147749311
11HumanObservational studyMechanism
In obese diabetic patients, the GH-related GDR increase correlated with the visceral-fat-to-muscle area ratio decrease (r=0.588, P=0.001).
In plain wordsIn obese diabetic patients, increased glucose disposal during GH was linked to a reduced visceral-fat-to-muscle area ratio.
Peptide
HGH (somatotropin)
Outcome
Not applicableGDR and visceral-fat-to-muscle ratio association
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.15 IU/kg body weight/week · 12 weeksAs given in this study (human).
Measurements
Correlation coefficient between GDR increase and decrease in visceral/muscle area ratio
0.588 r
GH-treated patients
Source sentences
Summary
The GH-induced increase in GDR was positively correlated with the decrease in the ratio of visceral fat area/muscle area (r=0.588, P=0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n=9; rhGH, 0.15 IU/kg body weight/week) or placebo (n=9) for 12 weeks.
Summary · context
Eighteen newly-diagnosed obese type 2 diabetic patients (age 42--56 y, body mass index 28.1+/-2.7 kg/m(2)).
Report a problemFND-1147749306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.